1. Introduction
===============

Approximately 200,000 patients develop Gram-negative sepsis each year in the USA [@bib1]. Of these, about one quarter develop acute respiratory distress syndrome (ARDS), and mortality is estimated at 60--90%. Despite the current detailed understanding of the pathology of sepsis, there are still few effective strategies against this condition [@bib2], [@bib3]. Interestingly, recent studies suggest that an inhibition of blood coagulation is beneficial [@bib4], [@bib5]. In addition to neutrophils and macrophages, an interaction between platelets and pulmonary endothelial cells may be involved in ARDS [@bib6]. Platelets also play an important role in the development of multiple organ failure in sepsis [@bib7].

Using 5-hydroxytryptamine (5HT) as a marker for platelets, we have recently demonstrated that within a few minutes of an intravenous injection of lipopolysaccharide (LPS) into mice, platelets accumulate in the lung and liver (particularly in the lung) [@bib8]. At lower doses of LPS, these platelets soon return to the circulation, but at higher doses they are broken down, with their large-scale breakdown inducing lethal shock [@bib9], [@bib10]. This response (the magnitude of which depends on the strain of mouse, the structure of the LPS, and its dose) is induced via an activation of the complement system [@bib9], [@bib10]. Thus, the rapid shock induced by LPS differs from the well-known "endotoxin shock" seen in mice in that in the latter type, shock signs appear 2--3 h or more later, with death occurring several hours or more later [@bib11]. It is thought that LPS is involved as a mediator in several of the signs seen in sepsis (including shock) and that various inflammatory cytokines (such as TNF and IL-1) are also involved in mediating these signs [@bib12], [@bib13], [@bib14].

Glycyrrhizin (GL) is a major constituent of aqueous extracts obtained from the root of the licorice plant. Orally administered GL is converted to its aglycon, 18β-glycyrrhetinic acid (GA), and GL and/or GA exhibit a variety of pharmacological activities, including anti-virus activity [@bib15], [@bib16] and anti-hepatitis activity [@bib17]. They also have anti-inflammatory activities via suppressions of prostaglandin production [@bib18], histamine release [@bib19], and histamine synthesis [@bib20], [@bib21]. In addition, GL and/or GA inhibit the complement system [@bib22], [@bib23]. In Japan, GL is given to chronic hepatitis C patients by daily slow intravenous infusions over a long period [@bib24], [@bib25]. Here, we examined the effects of GL and GA on the platelet response and ensuing rapid shock induced in mice by LPS.

2. Materials and methods
========================

2.1. Animals and materials
--------------------------

Male BALB/c mice (6--7 weeks old) were provided by the animal facility of our university. LPS from the *Klebsiella* O3 strain LEN-1 (S type) was prepared by the phenol-water method [@bib26], dissolved in sterile saline (0.1 or 0.5 mg/ml), then injected (i.v.) via the tail vein (0.1 ml/10 g body weight). A monoclonal anti-mouse platelet antibody, Pm-1, was kindly provided by Dr. T. Nagasawa (Division of Hematology, University of Tsukuba, Japan) [@bib27]. Although the molecular antigen for Pm-1 has not been identified, Pm-1 has been shown to deplete platelets in mice [@bib28]. Control IgG was prepared from normal mouse serum by precipitation with ammonium sulfate, followed by dialysis of the precipitant. Glycyron Injection (Minophagen Pharmaceutical, Tokyo, Japan) (a 26.5 mg/ml solution of ammonium glycyrrhizinate, equivalent to 20 mg/ml of GL) was diluted with saline, then injected intravenously (i.v.) or intraperitoneally (i.p.) (0.1 ml/10 g body weight). GA (Tokyo Kasei, Tokyo, Japan) was suspended in 1% carboxymethyl cellulose and given into the stomach through a syringe (0.1 ml/10 g body weight). Aspirin (Sigma, St. Louis, MO, USA) was dissolved in saline by adding 1 M NaOH, with the pH of the solution being adjusted to 7 with 1 M HCl. Dexamethasone (Sigma) was dissolved in saline. Before the experiment, mice were moved to a room with a temperature of 26--28 °C, and kept there for 1 h after injection of LPS, because the rapid platelet responses to LPS are reduced at room temperatures lower than that (unpublished data). In experiments intended to last a long time, mice were returned to a normal animal room (23±1 °C) at 1 h after the LPS injection. All procedures complied with the Guidelines for the Care and Use of Laboratory Animals in Tohoku University.

2.2. Platelet counting
----------------------

Two or three drops of blood from each decapitated mouse were directly collected into a pre-weighed test tube containing 1.0 ml of 4 mM EDTA in 0.01 M phosphate-buffered saline (pH 7.0). The tube plus blood was weighed, and the volume of blood was estimated from the weight of the blood. The number of platelets was then ascertained using a cell counter (Sysmex SF-3000; Toa Medical Electronics, Kobe, Japan) and expressed as platelet count/ml of blood.

2.3. Determination of 5HT
-------------------------

The 5HT levels in the blood and lung were determined as previously described [@bib8]. Briefly, after collecting the blood for measuring the platelet count (see above), the next two or three drops of blood from the same mouse were collected into another pre-weighed tube containing 3 ml of 0.4 M HClO~4~, 0.1% *N*-acetylcysteine-HCl, and 4 mM EDTA-2Na. After reweighing, the platelets were destroyed by sonication, and each tube was cooled in an ice bath. Lungs were rapidly removed and kept in a jar containing dry ice until needed. The determination of the 5HT level in the blood was carried out soon after the blood was collected, whereas the 5HT levels in the lung were determined within 2 days of collection. After 5HT had been separated by column chromatography, it was measured fluorometrically as previously described [@bib29]. The amount of 5HT in the blood or lung was expressed as nmol/g of blood or lung.

2.4. Scoring of the rapid shock induced by LPS
----------------------------------------------

The severity of the rapid shock seen in each mouse within 60 min of an LPS injection was scored as described elsewhere [@bib10], the scoring system being: 0 (no signs of shock), 1 (staggering), 2 (crawling and prostration), 3 (prostration and weak convulsions), 4 (prostration and strong convulsions), 5 (death). The shock-scoring data are expressed as scores for individual mice, or sometimes as mean±SD, as appropriate. The estimation of the scores was performed by a blinded assistant.

2.5. Statistical analysis
-------------------------

Experimental values for 5HT levels and platelet count are given as mean±S.D. The statistical significance of differences was assessed using a Student\'s unpaired *t*-test or a Bonferroni post-hoc test. The difference in shock scores between two experimental groups was analyzed using a Ridit (relative to an identified distribution) test [@bib30], a non-parametric test.

3. Results
==========

3.1. Effects of Pm-1
--------------------

Pm-1 induced an almost complete depletion of platelets from the blood within 3 h after its intravenous injection ([Fig. 1](#fig1){ref-type="fig"} ). The injection of Pm-1 also decreased 5HT in the blood, indicating that most of the 5HT in the blood is included in platelets. In this experiment, weak signs of shock (score 1--2) appeared at 10--60 min after the injection of Pm-1 itself. Control IgG did not change the platelet count or the 5HT in the blood ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Effects of Pm-1 on platelets and 5HT in the blood. Control IgG or Pm-1 (each, 12 mg/kg) was injected (i.v.) into mice. The blood of each mouse was collected by decapitation at the time indicated, then subjected to assays of platelet count and 5HT. Each value is the mean±S.D. from 4 mice. \**P*\<0.01 vs. control IgG.

In mice given control IgG, an intravenous injection of 1 mg/kg of LPS (given 12 h after the control IgG injection) induced severe shock signs (scores 3--4) within 10 min ([Table 1](#tbl1){ref-type="table"} ). However, most of the mice were alive 24 h later. In contrast, in mice given Pm-1 this dose of LPS induced no apparent shock signs within 1 h after the LPS injection; however, most of these mice died within 24 h ([Table 1](#tbl1){ref-type="table"}).Table 1Effects of Pm-1 on shock signs induced by LPSTreatmentShock score in each mouseSurvival after 24 hControl IgG3,4,4,4,4 (3.8±0.4[a](#tblfn1){ref-type="table-fn"})4/5Pm-10,0,0,0,1 (0.2±0.4[\*](#tblfn2){ref-type="table-fn"})1/5[^1][^2][^3]

3.2. Effects of GL
------------------

Before describing our results on platelets, we should emphasize the following point. As described previously [@bib31], the half-life of the intravenously injected 5HT in the blood is ≪10 s, although we cannot determine this time accurately. When we injected 5HT at a dose of 25 nmol per mouse, we could not detect any increase in 5HT in the blood at 10 s after the 5HT injection. Thus, the value given in the following sections for the amount of 5HT in the blood and lung may represent almost entirely the 5HT present within the platelets themselves.

As shown in [Fig. 2](#fig2){ref-type="fig"} , LPS at 1 mg/kg induced a rapid decline in both platelets and 5HT in the blood within 4 min after its injection, followed by a partial recovery at 10 min. Reciprocal changes were seen in 5HT in the lung. Following these changes, severe shock signs were seen about 6 min after the LPS injection (see inset table in [Fig. 2](#fig2){ref-type="fig"}). In Japan, GL is given by an intravenous drip infusion to patients with hepatitis. Thus, we first examined the effects of GL injected intravenously 10 min before an intravenous injection of LPS. In this experiment, GL (200 mg/kg) significantly reduced the changes in the blood and lung as well as the shock signs, that induced by 1 mg/kg of LPS ([Fig. 2](#fig2){ref-type="fig"}). GL itself at this dose had no significant effect on either the platelet count or the 5HT in the blood and lung ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 2Effects of GL on LPS-induced platelet responses and shock. Mice were given saline (S) or GL (200 mg/kg, i.v.), and 10 min later LPS was injected (1 mg/kg, i.v.). The mice were killed at 4 or 10 min after the injection of LPS. Then, platelet count and 5HT concentrations in the blood and lung were determined. Each value is the mean±S.D. from 4 mice. \**P*\<0.05 vs. saline group. The inset table shows maximum scores allocated for the shock signs observed in each mouse during the experiment. The difference in the scores between the S and GL groups was statistically significant (*P*\<0.05).Fig. 3Dose-dependent effects of GL. Mice were injected (i.v.) with saline (S) or the indicated dose of GL, and 10 min later LPS was injected (1 mg/kg, i.v.). The mice were killed at 10 min after the injection of LPS. Then, platelet count, 5HT concentrations in the blood and lung, and shock scores were determined. Each value is the mean±S.D. from 4 mice. \**P*\<0.05 and \#\#\<0.01 vs. S→LPS group.

Intravenous injection of 100 mg/kg of GL at 10 min before an LPS injection (1 mg/kg) also reduced both the 5HT increase in the lung and the severity of the shock ([Fig. 3](#fig3){ref-type="fig"}). However, when 200 mg/kg of GL was injected intravenously at an earlier time-point (viz. 30 min before the LPS), there was no significant effect (data not shown). Intraperitoneal injection of GL (100 or 200 mg/kg) at 30 or 60 min before LPS injection was not effective, either (data not shown).

Next, we examined the effects of simultaneous injection of GL and LPS. Lower doses of GL, at 40 and 80 mg/kg, significantly reduced the severity of the rapid shock induced by LPS (1 mg/kg), and they tended to improve the survival rate at 24 h after the injection of LPS ([Table 2](#tbl2){ref-type="table"} ).Table 2Effects of simultaneous injection of GL and LPS on the severity of rapid shock induced by LPSGL dose (mg/kg)Shock score in each mouseSurvival after 24 h03,3,4,5,5 (4.0±1.0[a](#tblfn3){ref-type="table-fn"})3/5202,2,3,5,5 (3.4±1.5)3/5402,2,3,4,4 (3.0±1.0)[\*](#tblfn4){ref-type="table-fn"}4/5802,2,2,3,4 (2.6±0.9)[\*](#tblfn4){ref-type="table-fn"}5/5[^4][^5][^6]

As shown in [Table 3](#tbl3){ref-type="table"} , intravenous injection of 5 mg/kg of LPS caused death in all mice within 1 h after the injection. Pretreatment with GL (200 mg/kg, intravenously) at 10 min before the LPS injection completely prevented the lethal effect of LPS, although LPS still induced shock scores of 2 to 4 in these mice.Table 3Effects of GL on the lethality induced by a lethal dose of LPSTreatmentShock score in each mouseSurvival after 24 hSaline+LPS5,5,5,5,5 (5.0±0.0[a](#tblfn5){ref-type="table-fn"})0/5GL+LPS2,3,3,4,4 (3.2±0.8)[\*](#tblfn6){ref-type="table-fn"}5/5[^7][^8][^9]

GL itself was lethal at 600 mg/kg or more, although at 400 mg/kg it produced no detectable abnormalities in the appearance or activity of mice ([Fig. 4](#fig4){ref-type="fig"} ). However, those mice that survived for 1 h after the GL injection (at 600 or 800 mg/kg) were all still alive at 24 h. These mice all looked healthy at 2 h or more after the injection of GL.Fig. 4Lethality induced by GL alone. GL was injected i.v. at the doses indicated.

Unlike that of GL, the solubility of GA in water is very low, and so GA is used clinically as an oral drug. We therefore tested the effect of orally administered GA on the LPS-induced rapid shock ([Fig. 5](#fig5){ref-type="fig"} ). Under our conditions, GA slightly reduced the severity of the shock only when it was administered at 500 mg/kg at 1 h before the LPS injection.Fig. 5Effects of GA. Mice were given GA orally at the indicated doses, then injected with LPS (1 mg/kg, i.v.) at the indicated times. "Shock score" indicates maximum score allocated for the shock signs observed within 30 min of the LPS injection. \#*P*\<0.05 vs. GA 0.

3.3. Effects of aspirin and dexamethasone, alone or in combination with GL
--------------------------------------------------------------------------

Non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids are widely used against a variety of inflammatory diseases. Aspirin is a typical NSAID and anti-platelet drug, while dexamethasone is a typical synthetic glucocorticoid. In various murine inflammation models, aspirin and dexamethasone are given intraperitoneally at 50--150 and 0.2--5 mg/kg, respectively. We previously reported that at these doses, aspirin and dexamethasone were effective at reducing the platelet responses induced by a low dose (0.25 mg/kg) of the same LPS as that used in the present study [@bib8] (this dose of the LPS produces shock scores of 0 to 1). Thus, in our next experiment we tested the effects of these drugs on both the platelet response and the severity of the rapid shock induced by 1 mg/kg LPS. At the above doses, these drugs increased the return of platelets to the circulation at 10 min after the injection of LPS, but their effects, although statistically significant, were not large ([Fig. 6](#fig6){ref-type="fig"} ). The effects of these drugs on the shock signs induced by 1 mg/kg of LPS were not significant ([Fig. 7](#fig7){ref-type="fig"} ). When aspirin or dexamethasone was given in combination with GL, however, each combination tended to reduce the severity of shock more effectively than GL alone ([Fig. 7](#fig7){ref-type="fig"}).Fig. 6Effects of aspirin and dexamethasone on LPS-induced platelet responses. Saline, aspirin (Asp, 100 mg/kg), or dexamethasone (Dex, 1 mg/kg) was injected (i.p.) at 90 min before an injection of LPS (1 mg/kg, i.v.). The data are the mean±SD from 5 mice. \**P*\<0.05 and \*\**P*\<0.01 vs. Saline group.Fig. 7Effects of GL in combination with aspirin or dexamethasone. Saline (S), aspirin (Asp, 100 mg/kg), dexamethasone (Dex, 1 mg/kg), or GL (200 mg/kg) was injected (i.p.) at 90 min before injection of LPS (1 mg/kg, i.v.). In other mice, GL (200 mg/kg) was injected (i.v.) at a time 90 min after the Asp or Dex injection and 10 min before the LPS injection. "Shock score" indicates maximum score allocated for the shock signs observed within 30 min after the LPS injection. The data are individual scores and the mean from 5 mice. \#*P*\<0.05 vs. S→LPS.

Finally, we compared the effects of GL, aspirin, and dexamethasone at the above doses on the lethality induced by 5 mg/kg of LPS ([Fig. 8](#fig8){ref-type="fig"} ). Although, as shown in [Fig. 7](#fig7){ref-type="fig"}, the effects of aspirin and dexamethasone on the LPS-induced rapid shock were marginal, these drugs prolonged survival time in mice given a lethal dose of LPS. On the other hand, the mice given GL all survived for at least 48 h after the LPS injection.Fig. 8Effects of GL, aspirin, and dexamethasone on the lethality induced by a lethal dose of LPS. Saline or GL (200 mg/kg) was injected (i.v.) 10 min before an injection of LPS (5 mg/kg, i.v.), while aspirin (Asp, 100 mg/kg) or dexamethasone (Dex, 1 mg/kg) was injected (i.p.) 90 min before an injection of LPS (5 mg/kg, i.v.).

4. Discussion
=============

The results obtained from the present experiment using Pm-1, a monoclonal antibody directed toward murine platelets, suggest that platelets are critical for the development of the rapid shock induced by LPS. However, the results suggest that they may also play an important role in helping the animal to resist the delayed lethality induced by LPS, the so-called "endotoxin shock". Our results demonstrate that GL is effective at suppressing not only the rapid shock induced by LPS, but also the delayed "endotoxin shock". In experimental models like that employed in the present study, we can distinguish between these rapid and delayed types of shock, because the LPS is given to animals by a single injection. In human patients, however, the level of endotoxin may increase progressively with the increase in bacterial numbers, and the pathology of Gram-negative sepsis may also develop progressively. Therefore, when the two types of shock occur in the same patient, distinguishing between them will be difficult. We speculate that infection with Gram-negative bacteria (or with LPS derived from them) may stimulate mechanisms leading to both types of shock. In the present study, we directed our attention mainly toward the rapid platelet responses to LPS and the associated rapid shock.

We earlier proposed that the lectin pathway that forms C3 convertase from C4 and C2 may be involved in the LPS-induced accumulation of platelets in the lung, while the pathway from C5 to C9 is involved in the subsequent platelet destruction and rapid shock [@bib9], [@bib10]. Interestingly, Kroes et al. [@bib22] reported that both GL and GA inhibit human complement C2 in vitro, while Fujisawa et al. [@bib23] found that GL inhibits human C5 or a later stage of the complement cascade in vitro. These effects are seen at 0.05--0.5 μmol/ml (about 0.05--0.5 mg/ml) of GL (this level of GL might have been attained in the blood in our in vivo experiment, as described below). In the present study, GL inhibited the LPS-induced accumulation of platelets in the lung. In addition, in GL-treated mice the platelet count in the blood had returned almost to its initial level at 10 min after the LPS injection, and the severity of the shock was markedly reduced. These results suggest that GL may inhibit both the early and later stages of the lectin pathway, although other anti-inflammatory effects of GL might also be involved. Interestingly, GL has recently been shown to inhibit thrombin-induced platelet aggregation both in vitro [@bib32] and in vivo models of thrombosis in rats [@bib33]. The dose- and time-dependent effects of GL on in vivo thrombosis that were observed in the latter study were very similar to those seen in the present study. The complement system is composed of several serine proteases [@bib34], [@bib35]. Upon recognition of pathogens, mannose-binding lectin (MBL) and ficolins trigger the activation of the lectin pathway through MBL-associated serine proteases (MASPs) [@bib35]. We have shown that activation of the lectin pathway is involved in the LPS-induced activation of platelets [@bib9], [@bib10]. MASP-1 has thrombin-like activity [@bib36] and thrombin is also a serine protease. Thus, it is likely that GL might exhibit its inhibitory action on the lectin pathway through its inhibitory effect on serine proteases. It should also be noted that many in vivo platelet responses are considered to be mediated, directly or indirectly, by activated complements, and the terminal complement proteins have been suggested to generate thrombin [@bib37]. In any event, we need to clarify the mechanism (possibly involving other anti-inflammatory effects of GL) by which GL suppresses the rapid platelet responses to LPS as well as the delayed lethality induced by LPS.

GL, at 100--200 mg/kg, was effective only when it was injected intravenously shortly before an LPS injection (i.e., at 10 min before, but not at 30 or 60 min before LPS), suggesting that an effective level of GL was not present at the later times. Indeed, lower doses of GL (40 and 80 mg/kg) were effective when injected (i.v.) simultaneously with LPS. These lower doses are equivalent to about 0.5--1 mg/ml in the blood (since the average mouse body weight is about 25 g and its blood volume about 2 ml). In chronic hepatitis C patients, GL is slowly infused intravenously at 2--4 mg/kg/day for a long period [@bib24], [@bib25], which would yield a concentration in the blood of about 0.025--0.05 mg/ml. Compared to this human dose, our murine doses seem to be very high. However, it should be noted that pharmacokinetic profiles differ greatly between mice and humans. This difference may be partly due to the difference in their heart rates: 50--70 and 400--600 beats/min in humans and mice, respectively [@bib38]. Thus, the blood concentration of drugs may decrease more rapidly in mice than in humans, which means that larger doses are needed in the former than in the latter. For example, in various murine inflammation models aspirin and dexamethasone are given intraperitoneally at about 50--150 and 0.2--5 mg/kg, respectively, while in humans the single oral doses of these drugs are roughly 10--20 and 0.01--0.05 mg/kg, respectively. Moreover, more than 80% of GL is cleared from the blood within 10 min of its intravenous bolus injection into mice [@bib39], while the initial half-life of GL in the blood is roughly 1 h in humans [@bib40]. In view of the information about in vitro concentrations given above, the slow intravenous infusion of GL typically used in humans might be expected to provide an effective blood concentration for the suppression or prevention of the platelet responses to LPS in human patients infected with Gram-negative bacteria.

Our results showed that GL itself was neither lethal nor toxic when injected intravenously into mice at 400 mg/kg. Those mice that survived for 1 h after a GL injection (at 600 or 800 mg/kg) were (a) all still alive at 24 h, (b) all apparently healthy at 2 h or more after the injection of GL, and (c) displayed no detectable abnormalities in either appearance or activity. Thus, the hypertonic nature of GL solutions might be involved, at least in part, in the rapid death we observed at 600 mg/kg or more of GL.

In some in vitro experiments, GA has been shown to be more potent than GL [@bib18], [@bib19], [@bib22]. Although we have no relevant data on mice, it has been reported that in rats the plasma levels of GA are \<0.1 and \<1 μg/ml at 4 and 12 h, respectively, after either oral administration or intravenous injection of GL at 10 mg/kg [@bib41]. However, in the present study the effect of an oral administration of GA (even at a large dose) was only marginal, suggesting that GL acts, not as GA, but as GL itself. It is also likely that if we could inject GA intravenously, GA might be effective at reducing the actions of LPS.

Although NSAIDs and glucocorticoids have been shown to protect experimental animals against endotoxin shock, the clinical usefulness of these drugs is controversial [@bib42], [@bib43], [@bib44]. In the present study, although aspirin and dexamethasone were effective to some degree at promoting the return of platelets to the circulation (suggesting that they reduced the degradation of platelets in the lung and/or liver), their effects were marginal, and their effects, if any, on the rapid shock were also marginal. In addition, it should be noted that glucocorticoids strongly suppress immune responses. In contrast, the side effects of GL are few and can be controlled, and it has been suggested that GL enhances cell-mediated immunity by enhancing the production of Th1 cytokines such as interferon [@bib45] or interleukin-12 [@bib46], [@bib47]. Incidentally, recent studies have demonstrated that histamine suppresses Th1 responses, but enhances Th2 responses [@bib48], [@bib49]. Interestingly, GL suppresses both histamine release [@bib19] and histamine synthesis [@bib20], [@bib21], suggesting that GL may, at least in part, enhance Th1 responses via a suppression of histamine release and/or synthesis.

Pulmonary embolism is a very common condition (about 500,000 events per year in the USA) with a variety of risk factors [@bib50], and platelets are important components of pulmonary emboli [@bib51]. As described in Introduction, many patients develop Gram-negative sepsis, and such patients have a high incidence of ARDS. Intravenous injection of various Gram-positive bacteria themselves also induces rapid shock [@bib52], and we have shown that platelets are involved in this shock, too [@bib53]. Infusion of *Streptococcus sanguis* into rabbits has been shown to induce a marked accumulation of platelets in the lung [@bib54]. Fungal cells also induce platelet responses similar to those induced by LPS (unpublished data). In view of the above, our findings may help in devising a strategy against not only Gram-negative sepsis, but also the pulmonary thromboembolism induced by a variety of risk factors, including various infectious diseases.

Early studies of severe acute respiratory syndrome (SARS), an infectious disease caused by a new coronavirus, have revealed thrombocytopenia as a common finding [@bib55], [@bib56]. Gram-negative bacterial infection or catheter-related sepsis is often evident in these patients, and a significant percentage (20%) develop ARDS within 3 weeks [@bib56]. Interestingly, Cinatl et al. [@bib57] recently reported that among all the compounds tested (including rivavirin, which is currently used for SARS), GL was the most active at inhibiting the replication of the SARS-associated virus in vitro (although admittedly the effective concentration of GL was markedly higher than those of the other drugs). Rivavirin has many toxic effects, including hemolysis and a drastic reduction in hemoglobin. Since rapid treatment of SARS (and also sepsis) is needed to prevent ARDS developing, and since the side effects of GL are few and can be controlled, Cinatl et al. [@bib57] proposed that GL may be an effective drug against SARS. The present results, including the finding that GL is effective at suppressing so-called "endotoxin shock", seem to support this proposal.
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[^1]: Control IgG or Pm-1 (each, 12 mg/kg) was injected (i.v.) into mice, and 12 h later LPS was injected (i.v.) at a dose of 1 mg/kg. "Shock score" indicates maximum score allocated for the shock signs observed within 60 min after the LPS injection.

[^2]: Mean±SD.

[^3]: *P*\<0.01 vs control IgG.

[^4]: A mixture of GL and LPS was injected (0.25 ml/mouse, i.v.). The dose of GL was 20, 40, or 80 mg/kg, while that of LPS was 1mg/kg. "Shock score" indicates maximum score allocated for the shock signs observed within 60 min after the LPS injection.

[^5]: Mean±SD.

[^6]: *P*\<0.05 vs GL 0.

[^7]: Saline or GL(200 mg/kg) was injected (i.v.), and 10 min later 5 mg/kg of LPS was injected (i.v.). "Shock score" indicates maximum score allocated for the shock signs observed within 60 min after the LPS injection.

[^8]: Mean±SD.

[^9]: *P*\<0.01 vs Saline+LPS.
